Wuhan Hiteck Biological Pharma Co Ltd (300683) - Total Liabilities
Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has total liabilities worth CN¥393.09 Million CNY (≈ $57.52 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Wuhan Hiteck Biological Pharma Co Ltd operating cash flow efficiency to assess how effectively this company generates cash.
Wuhan Hiteck Biological Pharma Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Wuhan Hiteck Biological Pharma Co Ltd to evaluate the company's liquid asset resilience ratio.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Addnode Group AB (publ)
ST:ANOD-B
|
Sweden | Skr7.07 Billion |
|
Yujin Robot Co. Ltd
KQ:056080
|
Korea | ₩31.33 Billion |
|
Beijing Tianyishangjia New Material Corp Ltd
SHG:688033
|
China | CN¥2.48 Billion |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
Korea | ₩71.79 Trillion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $628.44 Million |
|
Nufarm Ltd
AU:NUF
|
Australia | AU$2.47 Billion |
|
Sok Marketler Ticaret As
IS:SOKM
|
Turkey | TL57.09 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Wuhan Hiteck Biological Pharma Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Wuhan Hiteck Biological Pharma Co Ltd (300683) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Hiteck Biological Pharma Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below shows the annual total liabilities of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥525.05 Million ≈ $76.83 Million |
+10.37% |
| 2023-12-31 | CN¥475.73 Million ≈ $69.61 Million |
+28.16% |
| 2022-12-31 | CN¥371.20 Million ≈ $54.32 Million |
+4.72% |
| 2021-12-31 | CN¥354.46 Million ≈ $51.87 Million |
-23.21% |
| 2020-12-31 | CN¥461.62 Million ≈ $67.55 Million |
+12.86% |
| 2019-12-31 | CN¥409.03 Million ≈ $59.85 Million |
-8.24% |
| 2018-12-31 | CN¥445.77 Million ≈ $65.23 Million |
+67.82% |
| 2017-12-31 | CN¥265.62 Million ≈ $38.87 Million |
-20.91% |
| 2016-12-31 | CN¥335.87 Million ≈ $49.15 Million |
+21.81% |
| 2015-12-31 | CN¥275.74 Million ≈ $40.35 Million |
+4.14% |
| 2014-12-31 | CN¥264.78 Million ≈ $38.75 Million |
+42.03% |
| 2013-12-31 | CN¥186.42 Million ≈ $27.28 Million |
-- |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy fo… Read more